GlassScriptPhysician profile
James O Calder
NPI 1447667332
$1,633.30
in general payments reported to CMS, 2019-2025
31 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $413 · 2021: $347 · 2022: $556 · 2024: $14.49 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.76 | 2019-2022 | |
| Intuitive Surgical, INC. | $165.52 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.25 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $126.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $114.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $105.04 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $87.75 | 2022 | |
| Abbvie INC. | $84.44 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.54 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $49.85 | 2019-2021 | |
| Lilly USA, LLC | $44.80 | 2019-2022 | |
| Allergan, INC. | $44.36 | 2020 | |
| Daiichi Sankyo INC. | $43.16 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.66 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $32.10 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $30.21 | 2021 | |
| Eisai INC. | $29.82 | 2020 | |
| Sanofi-Aventis U.S. LLC | $29.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $28.90 | 2019-2020 | |
| Gilead Sciences, INC. | $27.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.44 | 2021 | |
| Mylan Specialty L.P. | $17.60 | 2021 | |
| Pfizer INC. | $17.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2022 | |
| Glaxosmithkline, LLC. | $14.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.36 | 2020 | |
| Sobi, INC | $13.52 | 2020 | |
| Neurelis, INC. | $13.22 | 2021 | |
| Sanofi Pasteur INC. | $12.27 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.37 | 2021 | |
| Horizon Therapeutics Plc | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Calder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.